In prostate cancer, LNCaP and 22Rv1 prostate cancer cells transiently overexpress androgen receptor splice variant-7 (AR-V7), and consequently activate the nuclear factor-kappa B (NF-κB) and upregulate interleukin (IL)-6 gene expression. Here, AR is linked to prostate cancer.